Amegakaryocytic Thrombocytopenia

Read full text Summarise with VIRAT
Authors: Chokri Ben Lamine, Thierry M Leblanc, Mahmoud Deeb Aljurf, Jean‐Hugues Dalle
Cited by: 0
References: 24

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare, inherited bone marrow failure (BMF) disorder characterized by severe thrombocytopenia due to the absence or marked reduction of megakaryocytes in the bone marrow. Caused by biallelic mutations in the MPL gene encoding the thrombopoietin (TPO) receptor, CAMT presents early in infancy with bleeding symptoms and often progresses to pancytopenia. Elevated thrombopoietin levels, normal platelet size, and lack of response to immune therapies support the diagnosis, which is confirmed through genetic testing. CAMT is classified into three subtypes based on disease severity and progression. The only curative treatment is hematopoietic stem cell transplantation (HSCT), with best outcomes achieved in early childhood before the onset of transfusion-related complications. Bone marrow is the preferred graft source. Supportive care, including transfusions and infection prophylaxis, remains critical prior to HSCT. Accurate early diagnosis and timely referral to transplant centers are essential to improve outcomes in this life-threatening disorder.

Fields of Study & Subjects

Platelet Disorders and Treatments Blood disorders and treatments Immunodeficiency and Autoimmune Disorders

Publication details

Journal / source
Springer eBooks
Pages
337–344
Publication date
25 March 2026
Language
EN
Document type
Book chapter